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DNA-encoded chemical libraries are promising tools
for the discovery of ligands toward protein targets
of pharmaceutical relevance. DNA-encoded small
molecules can be enriched in affinity-based selec-
tions and their unique DNA ‘‘barcode’’ allows the
amplification and identification by high-throughput
sequencing. We describe selection experiments
using a DNA-encoded 4000-compound library gener-
ated by Diels-Alder cycloadditions. High-throughput
sequencing enabled the identification and relative
quantification of library members before and after
selection. Sequence enrichment profiles corre-
sponding to the ‘‘bar-coded’’ library members were
validated by affinity measurements of single
compounds. We were able to affinity mature trypsin
inhibitors and identify a series of albumin binders
for the conjugation of pharmaceuticals. Furthermore,
we discovered a ligand for the antiapoptotic Bcl-xL
protein and a class of tumor necrosis factor (TNF)
binders that completely inhibited TNF-mediated
killing of L-M fibroblasts in vitro.
INTRODUCTION
The de novo identification of small organic molecules capable of
specific binding to protein targets is a central problem in chem-
istry, biology, and medicine. Conventional ligand discovery
methods in the pharmaceutical industry typically rely either on
high-throughput robotic screening procedures (with thousands
to millions of compounds being assayed separately), or on the
chemical improvement of candidate molecules with certain bio-
logical activities (Hajduk and Greer, 2007; Pellecchia et al., 2008;
Rees et al., 2004; Schreiber, 2000). Both approaches can be
expensive in terms of library-associated costs, logistics, and
availability of target protein in sufficient amounts. Furthermore,
one typically needs to develop a suitable assay (e.g., enzymatic
activity, ligand displacement) for screening purposes.
Affinity-based selection methods represent a novel avenue
for the discovery of binding molecules from large libraries ofChemistry & Biology 16, 1075–chemical compounds (Makara and Athanasopoulos, 2005).
Molecular entities capable of selective recognition of a target
protein of interest are typically isolated from a mixture of chem-
ical compounds by an affinity-capture procedure, followed by
a physical separation of the bound and unbound fractions. For
example, mixtures of compounds can be incubated with a target
protein in solution and preferential binders can be coeluted with
the protein in gel-filtration procedures and identified by liquid-
chromatography tandem mass spectrometry (MS) (Annis et al.,
2004; Muckenschnabel et al., 2004). This procedure is increas-
ingly being used in drug discovery programs (Zehender and
Mayr, 2007), but mixture size may be limited by MS detection
and compound solubility (Annis et al., 2004; Muckenschnabel
et al., 2004).
In principle, alternatives to MS identification of binding mole-
cules can be considered. For example, tagging individual
chemical compounds with unique DNA fragments serving as
amplifiable identification ‘‘bar-codes’’ may allow the facile
screening of very large libraries of small organic molecules (Bren-
ner and Lerner, 1992; Clark et al., 2009; Gartner et al., 2004; Hal-
pin and Harbury, 2004a; Mannocci et al., 2008; Melkko et al.,
2007a, 2004; Scheuermann et al., 2006). The screening of
DNA-encoded chemical libraries does not require the set-up of
a protein-specific functional assay (because molecules are
selected only on the basis of their ability to bind to an immobilized
protein) and can be performed when the amount of target protein
is limited (less than a milligram of protein per selection) (Melkko
et al., 2006). The technology is compatible with the use of low
concentrations of individual molecules, whose identity can be
revealed using polymerase chain reaction (PCR) procedures.
DNA-encoded chemical libraries can be synthesized in a
combinatorial fashion, because the DNA fragment itself can
facilitate library construction via different strategies. In self-
assembling chemical libraries (Melkko et al., 2004), each of two
complementary DNA strands is conjugated to a small molecule,
and the dual-molecule display allows the discovery of two ligands
in close proximity, in analogy to fragment-based approaches
(Blundell et al., 2002; Shuker et al., 1996). Other strategies for
library design include DNA template-assisted chemistry, using as-
sisting complementary oligonucleotides (Li and Liu, 2004) or DNA
three-way junctions to direct two chemical reactants (Hansen
et al., 2009). Alternatively, the solid-phase oligonucleotide-based
separation of DNA conjugates and subsequent chemical1086, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1075
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TNF Inhibitors from DNA-Encoded Chemical Libraryreactions (Halpin and Harbury, 2004a, 2004b; Halpin et al., 2004),
or the alternated stepwiseassemblyof chemicalmoietiesand cor-
responding DNA codes (Buller et al., 2008; Mannocci et al., 2008),
can be employed for DNA-encoded chemical library synthesis.
DNA-encoded library construction relies on methodologies
to synthesize DNA-conjugates at high yields and with good
purities while preserving the integrity of the oligonucleotides.
Until now many libraries are constructed using amide bond-
forming reactions (Halpin and Harbury, 2004a; Mannocci et al.,
2008; Melkko et al., 2004), yet other DNA-compatible reactions
could be considered. We recently described the synthesis and
characterization of a DNA-encoded chemical library, consisting
of 4000 compounds generated by Diels-Alder cycloaddition
reactions, each covalently attached to unique DNA fragments
(Buller et al., 2008). In this article, we present the results of
affinity-based selections using this 4000-member DNA-encoded
chemical library against different protein targets. DNA fragments
in the protein bound fraction were PCR amplified and the result-
ing amplicon mixtures were decoded with high-throughput
sequencing technology (‘‘454 technology’’) (Margulies et al.,
2005) to assess the relative abundance of library members
before and after selection against a target protein of interest.
In this article, we describe the statistical evaluation of the
sequencing data and subsequent hit validation by enzymatic
assays or affinity measurements. Using high-throughput
sequencing of the Diels-Alder library we identified ligands with
nanomolar to micromolar affinities, toward streptavidin, human
serum albumin, trypsin, Bcl-xL, and TNF, demonstrating the
applicability of DNA-encoded chemical libraries for the de novo
discovery of small molecules against a given protein target. The
discovery of a novel class of TNF binders capable of complete
inhibition of TNF-mediated cell killing in vitro suggests that it
should be possible to drug this proinflammatory cytokine with
small molecules. At the clinical level, TNF blockade has so far
only been accomplished with therapeutic proteins (Lin et al.,
2008), providing benefit to patients affected by chronic inflamma-
tory conditions and generating yearly sales of more than 10 billion
dollars. To our knowledge, although micromolar disruptors of
TNF integrity have previously been reported (He et al., 2005),
this is the first time that a TNF ligand was shown to completely
inhibit TNF-mediated cell killing in vitro.
RESULTS
Library Synthesis, Affinity-Based Selections,
and Decoding
Synthesis and characterization of the 4000-member DNA-
encoded chemical library generated by Diels-Alder cycloaddi-
tion reactions has been described in our previous publication
(Buller et al., 2008). In short, the synthesis was based on
a two-step split-and-pool strategy, with an initial coupling of
twenty 2,4-hexadiene derivatives of carboxylic acids via amide
bond formation to 42-mer 50 amino-modified oligonucleotides
carrying distinctive six-base codes (Figure 1A). As depicted in
Figure 1A, we performed cycloaddition reactions with a pool of
20 diene DNA-conjugates and 200 maleimides (generated from
the corresponding amines). After hybridization of a 44-mer
oligonucleotide fragment containing an eight-base code for the
second building block and a subsequent fill-in reaction mediated1076 Chemistry & Biology 16, 1075–1086, October 30, 2009 ª2009by Klenow DNA polymerase, reactions were pooled to yield
a 4000-member library (Figure 1A), which can be stably stored
frozen at 20C and used for selections.
For selections, the DNA-encoded chemical library was incu-
bated with the target protein immobilized on sepharose resin,
or with empty resin (tris[hydroxymethyl]aminomethane [Tris]
modified sepharose). Streptavidin, human serum albumin,
bovine trypsin, human Bcl-xL, and a murine TNF fusion protein
(EDB-TNF) were used as target antigens. Selections were per-
formed at a total DNA concentration of 10 nM, corresponding
to 2.5 pM concentration of individual library members. After
repetitive washing cycles binding library members were
captured on the resin as shown in Figure 1B. After selections,
DNA-conjugates retained on the resin were PCR amplified with
the primers 50-GCC TCC CTC GCG CCA TCA GGG AGC TTG
TGA ATT CTG G-30 and 50-GCC TTG CCA GCC CGC TCA
GGT AGT CGG ATC CGA CCA C-30, consisting of a 18 bp
complementary region to the library oligonucleotide tags and
19 bp overhang introducing the adaptor sites A and B, respec-
tively, which are essential for emulsion PCR and high-throughput
sequencing using the 454 technology. The general structure of
oligonucleotides in the amplicon mixture is depicted in Figure 1C.
High-throughput sequencing yielded up to 63,000 sequences for
each selection experiment, which were subsequently analyzed
by counting the frequency of each combination of the six-base
code 1 and eight-base code 2 and normalization to 50,000
sequences (see Figure 1C, Experimental Procedures).
High-Throughput Sequencing Enrichment Profiles
High-throughput sequencing results of the 4000 compound
library can be visualized in three-dimensional matrices, with
20 3 200 code combinations in the xy plane and sequence
counts for individual library codes on the z axis (Figure 2). As
expected, high-throughput sequencing of the naive library PCR
product before selection showed no significant enrichment of
specific codes. All sequence frequencies were lower than 42
counts, indicating a comparable abundance of the correspond-
ingoligonucleotide-compound conjugates (Figure2A; forastatis-
tical analysis of the results, see below). To verify library quality,
a test selection against streptavidin was carried out. The
sequence evaluation of the selection results indicated a strong
enrichment of compounds with code 2 = 200 (Figure 2B), which
corresponds to a D-desthiobiotin moiety as second building
block. This chemical structure is known to bind to streptavidin
in the nanomolar range (Table 1) (Dumelin et al., 2006; Hirsch
et al., 2002; Mannocci et al., 2008). The selection against immo-
bilized trypsin showed a striking enrichment of many compounds
containing code 2 = 6, which share the benzamidine moiety
(Figure 2C, Table 1). The panning experiment of the library against
the Tris-quenched resin (see above) led to the enrichment of
conjugates with code 2 of 120, 123, 136, 175 (see Figure S1 avail-
able online). These compounds are structurally related and were
omitted for ligand identification.
Panning of the library against human serum albumin resulted
in several hits as indicated by the enrichment profile depicted
in Figure 2D. Several enriched compounds were chosen for
resynthesis and affinity determination, including structures
with code 2 = 199, encoding a 4-(p-iodophenyl)butyl moiety,
previously discovered by DNA-encoded chemical libraryElsevier Ltd All rights reserved
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Figure 1. Ligand Discovery by DNA-Encoded Chemical Libraries
(A) Synthesis scheme of a 4000-member DNA-encoded chemical library using Diels-Alder cycloadditions. After coupling of twenty 2,4-hexadiene derivatives
(A 1-20) via amide bond formation to 42-mer amino-tagged oligonucleotides carrying code 1, the oligonucleotide conjugates were pooled. Cycloaddition reac-
tions were performed with 200 maleimides (B 1-200), which were derived from a condensation reaction of the corresponding amines and maleic anhydride (a). The
second building block B was encoded through hybridization and fill-in reaction mediated by Klenow DNA polymerase with an oligonucleotide fragment carrying
code 2. Finally, reactions were pooled yielding a 4000-member library.
(B) Selection for binders using a DNA-encoded chemical library. The 4000-compound library was panned against a target protein immobilized on sepharose
resin. Nonbinding conjugates were washed away before PCR amplification of the retained DNA conjugates. The resulting amplicon mixture was decoded using
high-throughput sequencing, allowing the relative quantification of all library members.
(C) General oligonucleotide sequence used for high-throughput sequencing.technology and displaying submicromolar affinity toward human
serum albumin (Figure 2D, Table 1) (Dumelin et al., 2008). The
selection experiment against Bcl-xL revealed a few codes with
frequencies of more than 40 counts, two of which were chosen
for hit validation (Figure 2E, Table 1). A selection against human
matrix metalloproteinase 3 however showed no significant
enrichment of any sequence (Figure S1), indicating that no
binding structures were present in the DNA-encoded 4000-
compound library. In the selection against EDB-TNF, we chose
the two most enriched DNA conjugates (10-171, 45 counts and
5-69, 41 counts) for hit validation (Figure 2F).
Statistical Analysis of High-Throughput
Sequencing Data
To our knowledge, a statistical analysis of the library decoding by
high-throughput sequencing has so far not been described inChemistry & Biology 16, 1075–the literature. In order to identify significantly enriched ligands
after selection, we compared the distribution of sequence
counts for members of a DNA-encoded chemical library in the
absence of selection pressure (PCR amplification of the library
before selection) with the sequence profiles in presence of
selection pressure (e.g., after capture on an immobilized target
protein).
High-throughput sequencing is based on random sampling of
beads resulting from emulsion PCR. Therefore, we consider the
negative binomial (NB) distribution as a good model for the anal-
ysis of the sequence counts, because this distribution describes
an experiment consisting of a series of independent events.
Specifically, sequence counts Yi (i = 1,.,4000) for the individual
compounds in the library, obtained prior to selection experi-
ments, are assumed to be independent and identically distrib-
uted (iid) samples from the NB distribution with mean and1086, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1077
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TNF Inhibitors from DNA-Encoded Chemical Libraryoverdispersion parameters q = (m,k). Note that the parameter k
represents the amount of overdispersion in Y relative to the
popular Poisson distribution, and when k / 0 the distribution
of Y becomes Poisson. We employed the method of maximum
likelihood in order to fit an NB model to the observed sequence
counts. Figure 3A displays the high-throughput sequencing of
the DNA-encoded chemical library before selection. All 4000
data points are shown by the histogram, whereas the solid curve
corresponds to the fitted NB probability density function with
mean 12.445 and overdispersion parameter 5.628. Similarly,
Figure 3B shows a quantile-quantile plot of the sample quantiles
versus the theoretical quantiles, indicating that the NB distribu-
tion fits the data very well.
Enrichment of DNA codes in the affinity-based selections was
addressed by calculating a one-sided p value for each of the
4000 library codes, using as a null hypothesis the NB probability
density function based on the library PCR before selection (i.e.,
the appropriate null hypothesis if sequence counts correspond-
ing to DNA-conjugates come from the equimolar mixture). A false
discovery rate multiplicity correction, level q = 0.1, was applied
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Figure 2. Sequence Enrichment Profiles after High-Throughput Sequencing of the DNA-Encoded Chemical Library
All 20 3 200 code combinations are plotted in the xy plane while the sequence counts for individual library codes are displayed on the z axis.
(A) Sequencing of the naive library (before selection).
(B–F) Selection experiments with the 4000-compound library against streptavidin (B), trypsin (C), human serum albumin (D), Bcl-xL (E), and EDB-TNF (F). Selec-
tions against Bcl-xL and EDB-TNF showed an enrichment of the background binders with code 2 equal to 120, 123, 136, 175, which are omitted from the
sequence enrichment profile for clarity (see Figure S1). The two arrows indicate TNF binders that were selected for further chemical optimization procedures.1078 Chemistry & Biology 16, 1075–1086, October 30, 2009 ª2009 Elsevier Ltd All rights reserved
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proportion of erroneously rejected null hypotheses (Benjamini
and Hochberg, 1995). This yielded for each selection a list of
significant candidate ligands, from which compounds were
chosen for further hit validation. As an example, Figures 3C
and 3D show the analysis of the high-throughput sequencing
of the trypsin selection. The decoding of the mixture exhibits
considerable deviations from the null distribution with notionally
equal abundance of all 4000 library members, indicating that
enriched DNA conjugates are present after selection.
Table 1. Summary of Selection Results and Ligand Binding
Chemistry & Biology 16, 1075–1086, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1079
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To evaluate the affinity of preferentially enriched compound-
DNA conjugates, we resynthesized individual compounds as
triethylene glycol-fluorescein-conjugates and measured the
dissociation constants by fluorescence polarization at 25C.
Streptavidin ligands showed dissociation constants between
185 nM and 422 nM, whereas the corresponding DNA conju-
gates were enriched with up to 426 sequence counts, resulting
in adjusted p values lower than 0.001 for all 20 conjugates
carrying a d-desthiobiotin moiety (Figure 4A). Structures, disso-
ciation constants and sequence counts are given in Table 1.
Compounds selected against human serum albumin showed
dissociation constants as low as 440 nM (compound 6-199)
and the selection process also allowed to identify a series of
novel binders in the 10 to 20 mM range, such as compound
6-79 with a Kd of 12 mM (Figure 4B). For comparison, the nonen-
riched compound 6-86 and 3-74 showed no specific binding to
human serum albumin, reflecting the difference between binders
and nonbinders in the selection and decoding process (Table 1).
Affinity-based selections against Bcl-xL lead to the enrich-
ment of several DNA conjugates (Figure 2E). Polarization
measurements with the fluorescein conjugate of compound
6-199 revealed a Kd of 10 mM, whereas the nonsignificant analog
1-199was interacting with the protein in the range of 100 mM and
compound 20-74 was nonbinding (Figure 4C, Table 1). The
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Figure 3. Statistical Analysis of the High-Throughput Sequencing
Decoding
(A) Histogram of the sequence counts obtained from high-throughput
sequencing of the DNA-encoded library before selection. The solid curve is
the fitted NB probability density function.
(B) Associated quantile-quantile plot of sample versus theoretical NB quan-
tiles, indicating good model fit.
(C) Histogram of the sequence counts after affinity-based selection against
trypsin. The solid curve is the same fitted NB probability density function as
in (A), i.e., prior to imposing selection pressure.
(D) Quantile-quantile plot of sample versus theoretical NB quantiles, where
deviations from the diagonal reveal interesting candidate compounds.1080 Chemistry & Biology 16, 1075–1086, October 30, 2009 ª2009 Eaffinity cut-off in this selection procedure is therefore likely to
be in the lower micromolar range. For comparison, the BH3I-1
compound described previously binds to Bcl-xL with a Kd of
4.4 mM (Figure S3) (Degterev et al., 2001).
The trypsin selection revealed a pronounced enrichment of
compounds containing the benzamidine moiety that were resyn-
thesized and measured in an inhibition assay using Z-GGR-AMC
as substrate (Figure 4D, Supplemental Data). This led to the iden-
tification of compound 12-6with a Ki of 11 mM and 235 sequence
counts, whereas compound 1-6 with 34 sequence counts
showed a Ki of 220 mM (Table 1).
Two significantly enriched DNA conjugates in the TNF selec-
tion were synthesized as fluorescein conjugates revealing a Kd
of 20 mM for compound 10-171 and a Kd of more than 50 mM
for compound 5-69, as measured by fluorescence polarization
against the trimeric EDB-TNF protein (Figure 4E). The fusion
protein EDB-TNF was chosen because of its good expression
yields in HEK293 cells, high stability, ease of purification, and bio-
logical activity. For comparison, a series of nonenriched library
analogs was synthesized, showing weaker or no binding in this
assay (Table 2, Figure 4E, Supplemental Data). The binders
were TNF specific, because no binding of the ligands toward
recombinant EDB was observed (Figure S2). We prepared
analogs 1a-b and 2a-c, based on the dichloro-benzophenone
moiety, in order to increase affinity, reduce stereochemical
complexity and introduce more hydrophilic residues, leading to
compounds 1b (Kd = 10 mM) and 2c (Kd = 15 mM; Table 2, Fig-
ure 4E and Figure S2). As depicted in Figure 4F, the free carbox-
ylic acid analog of this compound showed a complete inhibition
of recombinant murine TNF induced apoptosis in murine L-M
fibroblasts cells (Halin et al., 2003) at concentrations higher
than 300 mM, whereas nonrelated compounds (N1-N5) showed
no inhibition of TNF-mediated killing. Importantly, the compound
did not exhibit any toxicity toward L-M fibroblasts up to 500 mM
concentrations (Figure 4F).
DISCUSSION
We have synthesized and characterized a high-quality DNA-
encoded chemical library containing 4000 members generated
via Diels-Alder cycloaddition (Buller et al., 2008). High-yield reac-
tions were a key factor in the construction of the library, under-
lined by the analytical profiles previously reported by the group
on the purity of library members (Buller et al., 2008) and by the
statistical analysis of sequence counts to display a homogenous
distribution of different library members. Affinity-based selec-
tions using the library revealed that DNA-encoded compounds
specific to certain protein targets, with binding affinities lower
than 20 mM, could be enriched using affinity capture methodolo-
gies. High-sequencing counts (above 40 counts) led to the direct
identification of ligands, with a very low false-positive rate (only
compound 20-74 was later identified to be a false-positive in
the Bcl-xL selection). Even though factors of solid-phase medi-
ated selections, e.g., the influence of matrix material and protein
density, might impede an exact correlation between sequence
counts and affinity, the technology allows a clear differentiation
between nonbinders and ligands. Thus, we could discover novel
ligands toward human-serum albumin, trypsin, Bcl-xL, and TNF,
which were then characterized by fluorescence polarizationlsevier Ltd All rights reserved
Chemistry & Biology
TNF Inhibitors from DNA-Encoded Chemical Library10-171
5-69
1b
12-69
2c
]
P
m[
]
P
m[
]
P
m[
]
P
m[ evil a sll ec f o egat necr ep
100
0
2c
2c, no TNF
N1
N2
N3
N4
N5
A B
C D
E F
Figure 4. Binding Analysis by Fluorescence Polarization and Inhibition Measurements
Dissociation constants of selected compounds were determined by fluorescence polarization (A–C). Individual compounds identified in the high-throughput
sequencing decoding were synthesized as fluorescein conjugates and incubated with different concentrations of the target proteins streptavidin (A), human
serum albumin (B), and Bcl-xL (C). Binding molecules with a Kd as low as 184 nM to streptavidin (A), 440 nM to human serum albumin (B), and 10 mM to Bcl-xL
(C) were identified. Trypsin inhibition (D) was measured by incubating 2 nM bovine pancreatic trypsin with varying concentrations of the identified ligands without
oligonucleotide tag. Inhibitory constants of enriched compounds ranged from 11 mM (compound 12-6) to 49 mM (compound 19-6), whereas the nonenriched
analog 1-6 exhibited a Ki of only 220 mM. TNF ligands showed a Kd as low as 10 mM, measured by fluorescence polarization against the trimeric EDB-TNF protein
(E). Biological activity of 2c (in the free carboxylic acid form, i.e., without fluorescein tag) was confirmed in a TNF cytotoxicity assay on murine L-M fibroblasts (F),
providing complete inhibition of TNF-mediated cell killing (standard error of the mean is shown). The same agent did not show any toxicity to the cells when used in
the absence of TNF (empty circles). By contrast, nonrelated compounds used as negative controls did not exhibit any inhibition of TNF-mediated killing (non-
related compounds: naphthylacetic acid (N1), 2-(3-bromophenyl)acetic acid (N2), 3-(4-Methylpiperazin-1-yl)propan-1-amine (N3), 3-(phenylsulfonyl)propanoic
acid (N4), 4-Morpholinoaniline (N5); dashed line: DMSO control with no TNF present). Structures and affinity constants can be found in Tables 1 and 2.Chemistry & Biology 16, 1075–1086, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1081
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assays.
In this article, we have shown that a NB distribution could be
used to adequately describe sequence count profiles of the
DNA-encoded chemical library before selection. By contrast,
sequence counts after selection could be matched against the
null hypothesis of no enrichment, thus offering a statistical basis
for the identification of potential protein-specific ligands. As
sequencing power of novel high-throughput methodologies
increases (Pettersson et al., 2009), it might become possible to
oversample larger libraries before and after selection, thus
allowing similar statistical analyses of decoding results.
In contrast to phage display and ribosome display selection
methodologies, in which multiple rounds of panning and amplifi-
cation are needed for the identification of preferential binding
molecules (Silacci et al., 2005; Winter et al., 1994; Zahnd et al.,
2007), sequence-based enrichment profiles of DNA-encoded
chemical libraries allow the identification of preferential binders
without the need to reamplify/resynthesize the DNA-encoded
chemical library.
Because the Diels-Alder DNA-encoded chemical library
consists of two sets of independent building blocks, it could be
expected that both chemical moieties in a given compound
positively or negatively contribute to the overall binding perfor-
mance. This is clearly exemplified in the analysis of the series
of trypsin binders, which contain a benzamidine moiety. A series
of simple benzamidine derivatives was previously shown to
display Ki values to trypsin ranging between 11 and 220 mM
(for example, a Ki = 90 mM was reported for 4-(aminomethyl)ben-
zamidine) (Melkko et al., 2007b). We observed Ki values ranging
between 11 and 49 mM (for preferentially enriched compounds;
Figure 4D), in contrast to a Ki = 220 mM value for compound
1-6, which was not preferentially enriched in the selection. We
have also previously shown that micromolar benzamidine-based
trypsin binders could be subjected to affinity maturation proce-
dures using DNA encoded chemical libraries (Melkko et al.,
2007b). In addition to the de novo identification of molecules
endowed with biological activity, DNA-encoded chemistry might
represent an efficient avenue for the isolation of building blocks
that can be used in fragment-based drug discovery programs
(Hajduk and Greer, 2007; Pellecchia et al., 2008; Rees et al.,
2004).
Although for trypsin and streptavidin the best binders con-
tained moieties, previously described by our group and others,
that were known to contribute to specific protein recognition,
novel molecular entities were identified against three proteins
Table 2. TNF Selection Results and Ligand Binding1082 Chemistry & Biology 16, 1075–1086, October 30, 2009 ª2009 Elsevier Ltd All rights reserved
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TNF. Albumin represents the most abundant protein in human
plasma (45 mg ml1) and features a long circulatory half-life
thanks to its size above the renal filtration threshold and its
unique ability to interact with the neonatal FcRn receptor (Ander-
sen et al., 2006). Albumin binding pharmaceuticals (Dennis et al.,
2002; Nguyen et al., 2006; Syed et al., 1997) make it possible to
adjust the exposure of the body to adequate concentrations of
the therapeutic agents by increasing their serum half-life. Indeed,
certain albumin binders, such as derivatives of 4-iodophenylbu-
tyric acid, could lead to the improvement of pharmacokinetic
profiles of therapeutic agents and of contrast agents for imaging
applications (Dumelin et al., 2008). Certain molecules identified
from the selection with the 4000-membered library, such as
compound 6-79 (Kd 12 mM) or 7-70 (Kd 17 mM) (Figure 4B and
Table 1), corresponded to novel chemical structures, which
have so far not been associated with albumin binding.
Bcl-xL is a promising target in cancer therapy, because it is
known to signal for cell survival upon heterodimerization with
other proteins of the Bcl-2 family (Diaz et al., 1997; Marzo and
Naval, 2008; Vander Heiden and Thompson, 1999). In principle,
small-molecule inhibitors can disrupt Bcl-xL interactions with its
binding partners, thus altering the proapoptotic balance within
the cell. Recently, novel small-molecule ligands capable of inhib-
iting Bcl-xL protein-protein interactions in the nanomolar to
micromolar range have been described (Azmi and Mohammad,
2009) and several compounds are currently in clinical develop-
ment: For example, (-)-Gossypol, a polyphenolic aldehyde
(molecular weight [MW] = 519 g/mol, Ki = 480 nM) (Wang et al.,
2006) has been shown to be a potent inhibitor of cell growth
and clinical trials are ongoing (Kitada et al., 2003; Ko et al.,
2007; Van Poznak et al., 2001). The Bcl-xL inhibitor ABT-263
(MW = 975 g/mol, Ki = 0.5 nM) (Tse et al., 2008), which has
been shown to have potent cytotoxicity in vitro, is currently
tested in phase I/II clinical trials (Lock et al., 2008; Azmi and
Mohammad, 2009). Our discovery of compound 6-199 as a
Bcl-xL binder (Kd = 10 mM) might allow future affinity improve-
ment, either by a medicinal chemical approach or by the
construction of DNA-encoded affinity maturation libraries that
contain this chemical moiety. Compound 6-199 was found to
display an affinity to Bcl-xL that is comparable to the BH3I-1
ligand recently described in the literature (Kd = 4.4 mM; Figure S3)
(Degterev et al., 2001). The BH3I-1 ligand was identified in
a screening of 16,320 individual compounds, by competition
measurements of a fluorescently-labeled peptide derived from
the Bcl-xL interaction partner Bak. Future studies will elucidate
whether 6-199 is capable of inhibiting protein-protein interac-
tions with other Bcl-2 family members and can function in vivo.
The proinflammatory cytokine TNF represents a target of great
pharmaceutical interest, because it is crucial for the establish-
ment and maintenance of inflammation in multiple autoimmune
diseases. TNF blockade has proven to be an efficient treatment
of a number of human diseases such as rheumatoid arthritis,
inflammatory bowel disease, psoriatic arthritis, psoriasis, and
others (Lin et al., 2008). Three TNF antagonists are broadly
used in the clinical practice: the monoclonal antibodies adalimu-
mab and infliximab and a soluble receptor etanercept, but the
current injectable protein therapies have also associated risks
and limitations (Wong et al., 2008). The clinical use of an orallyChemistry & Biology 16, 1075–available drug, which interferes with TNF biology, is so far limited
to TNF synthesis inhibitors or intracellular pathway inhibitors that
antagonize nuclear factor kB (Palladino et al., 2003) The direct
disruption of protein-protein interactions such as the TNF inter-
action with its receptors remains a difficult challenge in drug
discovery (Wells and McClendon, 2007). He at al. were the first
to discover a small molecule that acts directly on TNF, inhibiting
its receptor interaction in the micromolar range by destabilization
of the trimeric complex (He et al., 2005). Our DNA-encoded
library selection against TNF led to the identification of novel
lead structures binding to TNF in the low micromolar range,
which proved to have a direct effect on cell survival in a TNF
cytotoxicity assay, therefore presenting promising structures
for future medicinal chemistry optimization.
Our identification of specific ligands from a 4000-compound
DNA-encoded chemical library using high-throughput
sequencing and the statistic analysis are encouraging for the
construction of future libraries of more than 106 compounds:
orthogonal synthetic procedures are necessary to react the first
building block A with two chemical moieties B and C. Upon intro-
duction of a second functional group besides the diene-moiety
on the first building block A (e.g., free amino groups are compat-
ible with the Diels-Alder reaction performed on oligonucleotides
[data not shown]), the displayed chemical moieties A can be
further diversified using two split and pool synthesis rounds. In
this case, two codes for the last two reaction steps can be intro-
duced in a sequential manner (Clark et al., 2009; Mannocci et al.,
2008). Recent advances in high-throughput DNA sequencing
indicate that it should be possible to sequence more than 1
million sequence tags per sequencing run (Pettersson et al.,
2009). Thus, selections and decoding of DNA-encoded libraries
containing millions of chemical compounds can be performed,
and facilitate the identification of binding molecules for pharma-
ceutical applications.
SIGNIFICANCE
DNA-encoded chemical libraries represent a new tool for the
identification of small organic molecules capable of specific
binding to proteins of biomedical relevance, thus contrib-
uting to the pharmaceutical lead discovery process. In this
article, we demonstrate that a DNA-encoded chemical
library, constructed via Diels-Alder cycloaddition reactions,
could be used in affinity-capture procedures for the identifi-
cation of binders to four proteins chosen as targets for
our selections. Decoding library composition by high-
throughput sequencing enabled the relative quantification
of library members before and after affinity capture and
allowed the discovery of novel specific ligands. Statistical
analysis of sequence data provided an objective avenue
for the identification of candidate molecules that are signif-
icantly enriched after affinity-based selections using high-
throughput DNA sequencing procedures. This work
provides the basis for the construction and decoding of
DNA-encoded chemical libraries of larger size (e.g., > 106
members), generated by split and pool procedures with
three sets of building blocks, offering a fast and cheap
alternative to conventional high-throughput small-molecule
screening.1086, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1083
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General Methods
All chemicals were purchased from Sigma-Aldrich-Fluka (Buchs, Switzerland),
ABCR (Karlsruhe, Germany), VWR (Leicestershire, England), or Bachem
(Bubendorf, Switzerland). Enzymes were purchased from New England Bio-
labs (Ipswich, MA) and high-pressure liquid chromatography (HPLC) grade
lyophilized DNA oligonucleotides were purchased from IBA GmbH (Go¨ttingen,
Germany) or Sigma-Aldrich (Buchs, Switzerland). Streptavidin-sepharose
slurry and CNBr-modified sepharose resin were purchased from GE Health-
care. Human MMP-3 catalytic domain (Scheuermann et al., 2008), Bcl-xL
(Manion et al., 2004), and the ED-B domain of fibronectin (Carnemolla et al.,
1996) were expressed as described previously. Recombinant mouse TNF
was purchased from eBioscience (San Diego, CA). The EDB domain of fibro-
nectin (Zardi et al., 1987) was fused to mouse TNF with a (SSSSG)3 linker to
improve solubility and facilitate purification. The resulting gene was cloned
into the mammalian cell expression vector pcDNA3.1 (Invitrogen, Basel,
Switzerland). The protein was expressed in HEK293 cells and purified via
anion-exchange chromatography. Biological activity of the TNF constructs
was confirmed as described previously (Halin et al., 2003). SpinX columns
were purchased from Corning Costar Incorporated (Acton, MA). HPLC purifi-
cations were performed on a Waters 2795 Alliance system with a Synergi
Polar-RP18 column (4 mm, 10 3 150 mm, Phenomenex, Torrance CA) using
a linear gradient from 0% to 100% MeCN with 0.1% TFA. Electrospray ioniza-
tion MS was performed on a Waters Quattro Micro spectrometer (Waters,
Milford, MA). Statistical computation was carried out using R version 2.8.1
and the multtest package, available from the Comprehensive R Archive
Network (http://cran.r-project.org/) under the terms of the GNU General Public
License.
Preparation of Target Protein Resin
CNBr-modified sepharose (100 mg, GE Healthcare) was thoroughly washed
with cold 1 mM HCl and incubated overnight at 4C either with 100 mg/ml
human serum albumin (in 100 mM NaHCO3, 0.5 M NaCl [pH 9]), 1 mg/ml trypsin
(in 100 mM NaHCO3, 0.5 M NaCl [pH 8.3]), 1.6 mg/ml MMP-3 (in 100 mM
NaHCO3, 0.5 M NaCl [pH 8.3]), 1.4 mg/ml Bcl-xL (in phosphate-buffered saline
[PBS] [pH 7.4]), 2.3 mg/ml EDB-TNF (in PBS [pH 7.4]), or with 1 M Tris/HCl
(pH 8.9) (Tris-quenched resin). MMP-3 resin was prepared and used as
described previously (Scheuermann et al., 2008). After coupling, resins were
washed repeatedly with alternating buffers (100 mM HOAc/NaOAc, 0.5M
NaCl [pH 4.7] and 0.1 M Tris/HCl, 0.5 M NaCl [pH 8]) using SpinX columns.
Before selection, resins were preincubated with PBS and 0.2 mg/ml herring
sperm DNA.
Selection for Binding
The DNA-encoded 4000-compound library (Buller et al., 2008) was diluted in
PBS to a final concentration of 20 nM and 50 ml was added to 50 ml sepharose
resin slurry, carrying the immobilized target protein, or to Tris-quenched
sepharose resin. After incubation for 1 hr at room temperature, the mixture
was transferred to a SpinX column, the supernatant was removed, and the
resin was washed five times with 400 ml PBS containing 1 mM MgCl2. Subse-
quently the resin was resuspended in 100 ml H2O.
Decoding by High-Throughput Sequencing
After selections, the codes of the oligonucleotide-compound conjugates were
amplified by PCR (50 ml reaction, 25 cycles of 1 min at 98C, 1 min at 50C, 30 s
at 72C, with Phusion High-Fidelity DNA Polymerase, New England Biolabs)
using 5 ml resuspended resin as a template. For an analysis of the library before
selection, the library was diluted to 1 nM and 5 ml was used as a template for
PCR amplification. The PCR primers P1_HTS (GCC TCC CTC GCG CCA TCA
GGG AGC TTG TGA ATT CTG G) and P2_HTS (GCC TTG CCAGCCCGC TCA
GGT AGT CGG ATC CGA CCA C) contain at the 50-extremity a 19-base domain
(italicized) required for high-throughput sequencing with the 454 genome
sequencer system. The PCR products were purified by agarose gel electro-
phoresis and subsequent ion-exchange cartridge purification and ethanol
precipitation of the DNA. High-throughput sequencing was performed on
a 454 Life Sciences-Roche GS 20 sequencer platform (sequencing service
by Roche USA). Analysis of the sequences was performed by an in-house1084 Chemistry & Biology 16, 1075–1086, October 30, 2009 ª2009program written in C++. The frequency of each code was assigned to each
individual compound-conjugate, after normalization to 50,000 sequences
per experiment.
Affinity Measurements
Fluorescein conjugates (500 nM, Syntheses, see Supplemental Data) were
incubated with increasing amounts of protein in PBS containing 1.7% dimethyl
sulfoxide (DMSO), for 1 hr at 25C. Fluorescence polarization was determined
with a TECAN Polarion instrument. The change of polarization signal was
plotted against the corresponding protein concentrations, and the KD value
was obtained by fitting with equation y = a + b 3 0.5 3 (((x + const + c) – sqrt
((x + const +c)2 – 43 const3 x))) (const = 500 nM, total ligand concentration).
Trypsin Inhibition Assay
Bovine pancreatic trypsin (2 nM) in PBS (20mM NaH2PO4, 30 mM Na2HPO4,
100 mM NaCl [pH 7.4], containing 5% DMSO) was incubated with varying
concentrations of inhibitors in 96-well microtiter plates (Nunc, Roskilde,
Denmark) for 30 min at room temperature (Syntheses, see Supplemental
Data). The reaction was started by the addition of the fluorogenic substrate
Z-GGR-AMC (Bachem, Bubendorf, Switzerland) dissolved in PBS to an end
concentration of 0.1 mM in a total volume of 100 ml. The change of fluores-
cence signal (ex: 383 nm; 455 nm; cutoff filter: 420 nm) was recorded over
10 min using a SpectraMax microplate reader (Molecular Devices). The rate
of fluorescence signal increase over time (reaction velocity v) was plotted
against the corresponding inhibitor concentrations, and the Ki value for the
inhibitor was obtained by fitting with equation v = vmax/(1+[I0]/Ki) ([Io]: inhibitor
concentration).
TNF Inhibition Assay
TNF bioactivity was determined by performing a cytotoxicity assay on murine
L-M fibroblasts (Corti et al., 1994; Halin et al., 2003). L-M fibroblasts were
grown in DMEM containing 10% FCS and antibiotic-antimycotic solution (Invi-
trogen) and seeded in 96-well plates at 30,000 cells/well in 100 ml medium.
Recombinant mouse TNF (final concentration of 3 pM trimer) was preincu-
bated for 30 min at room temperature with varying concentrations of inhibitors
in media containing actinomycin-D (final concentration of 2 mg/ml) and DMSO
(2% of the final concentration) (Syntheses see Supplemental Data). After
addition of the TNF compound mixture (50 ml), cells were incubated for 24 hr
at 37C, 5% CO2. Next, a solution of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carbox-
ymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (30 mL, CellTiter 96
AQueous Assay, Promega, Madison, WI) was added and plates were incu-
bated for an additional 2 hr at 37C, 5% CO2. Plates were then read at
490nm using a VersaMax microplate reader (Molecular Devices).
SUPPLEMENTAL DATA
Supplemental Data include three figures and Supplemental Experimental
Procedures and can be found with the article online at http://www.cell.com/
chemistry-biology/supplemental/S1074-5521(09)00321-4.
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